Table 1 Clinical characteristics of subjects suspected of having active COVID-19 (Cohort 1) and comparisons between patients with detectable and undetectable IgGs.
From: Detection of SARS-CoV-2 antibodies is insufficient for the diagnosis of active or cured COVID-19
Cohort 1 | Subjects with proven/probable COVID-19 | ||||
|---|---|---|---|---|---|
Overall | Proven/Probable COVID-19 | COVID-19 free | IgG-positive | IgG-negative | |
Median age, in years (IQ range) | 56 (45.5–68) | 56 (46.25–67.8) | 50 (35.5–70.5) | 60 (47–69.5) | 53.5 (44.75–63.5) |
Male | 36 (60%) | 36 (64.3%) | 3 (33.3%) | 22 (64.7%) | 14 (63.6%) |
Presence of symptoms | 100% | 100% | 100% | ND | ND |
Days from onset of symptoms to serum sampling (IQ range) | 7 (4.25–10) | 7 (5–10) | 5 (3–6.5) | 7 (5–13.25) | 7 (4–10) |
Fever (> 38 °C) | 55 (84.6%) | 49 (87.5%) | 6 (66.7%) | 27 (79.4%) | 22 (100%) |
Headache | 11 (16.9%) | 11 (19.6%) | 9 (100%) | 5 (14.7%) | 6 (27.3%) |
Cough | 53 (81.5%) | 48 (87.5) | 5 (55.6%) | 30 (88.2%) | 18 (81.8%) |
Asthenia | 32 (49.2%) | 29 (51.8%) | 3 (33.1%) | 17 (50%) | 12 (54.5%) |
Myalgia | 19 (29.2%) | 18 (32.1%) | 1 (11.1%) | 9 (26.5%) | 9 (40.9%) |
Sore throat | 2 (3.1%) | 1 (1.8%) | 1 (11.1%) | 0 (0%) | 1 (4.5%) |
Runny nose | 3 (4.6%) | 1 (1.8%) | 2 (22.2%) | 1 (2.9%) | 0 (0%) |
Dyspnoea | 40 (61.5%) | 34 (60.7) | 6 (66.7%) | 24 (70.6%) | 10 (45.5%) |
Pneumonia | 53 (81.5%) | 53 (94.6%) | 0 (0%) | 34 (100%) | 19 (86.4) |
Anosmia | 7 (10.8%) | 6 (10.7%) | 1 (11.1%) | 2 (5.9%) | 4 (18.2%) |
Ageusia | 6 (9.2%) | 5 (8.9%) | 1 (11.1%) | 1 (2.9%) | 4 (18.2%) |
Abdominal pain | 4 (6.2%) | 1 (1.8%) | 3 (33.3%) | 0 (0%) | 1 (4.5%) |
Diarrhoea | 24 (36.9) | 20 (30.7%) | 4 (44.4%) | 10 (29.4%) | 10 (45.5%) |
Hospital admission | 45 (59.2%) | 42 (75%) | 3 (33.3%) | 27 (79.4%) | 15 (68.2%) |
Death | 6 (9.2%) | 5 (8.9%) | 1 (11.1%) | 2 (5.9%) | 3 (13.6%) |
Positive IgG | 34 (52.3%) | 34 (60.7%) | 0 (0%) | NA | NA |
Number of patients | 65 | 56 | 9 | 34 | 22 |
